<!DOCTYPE html><html><head><title>Lipid management in adults: percentage of patients with established ASCVD, or a 10-year CHD risk greater than or equal to 10%, or diabetes on lipid-lowering medication and most recent LDL greater than 100 mg/dL, who are prescribed a maximal recommended dose of a potent statin (such as simvastatin, pitavastatin, rosuvastatin or atorvastatin).</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Title
</h3>
<div class='FieldValue'>
<div class="content_title">Lipid management in adults: percentage of patients with established ASCVD, or a 10-year CHD risk greater than or equal to 10%, or diabetes on lipid-lowering medication and most recent LDL greater than 100 mg/dL, who are prescribed a maximal recommended dose of a potent statin (such as simvastatin, pitavastatin, rosuvastatin or atorvastatin).</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Woolley T, Canoniero M, Conroy W, Fareed M, Groen S, Helmrick K, Kofron P, Kottke T, Leslie S, Myers C, Needham R, O'Connor P, Peters J, Reddan J, Sorge L, Zerr B. Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2013 Nov. 49 p.  [88 references]</td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Measure Domain
</h2>
<div class='field field_picklist-one'>
<h3>
Primary Measure Domain
</h3>
<div class='FieldValue'>
Clinical Quality Measures: Process
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Secondary Measure Domain
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>

</div>
<div class='section'>
<h2>Brief Abstract
</h2>
<div class='field field_text'>
<h3>
Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure is used to assess the percentage of adult patients with:</p>
<ol style="list-style-type: lower-alpha;" start="1">
    <li>Established atherosclerotic cardiovascular disease (ASCVD), or </li>
    <li>A 10-year coronary heart disease (CHD) risk greater than or equal to 10%, or </li>
    <li>Diabetes </li>
    <li>On lipid-lowering medication, and </li>
    <li>Most recent low-density lipoprotein (LDL) greater than 100 mg/dL, who are prescribed a maximal recommended dose of a potent statin (such as simvastatin, pitavastatin, rosuvastatin or atorvastatin). </li>
</ol></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rationale
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The priority aim addressed by this measure is to increase the percentage of patients with established atherosclerotic cardiovascular disease (ASCVD), or 10-year coronary heart disease (CHD) risk greater than or equal to 10%, or diabetes and on lipid-lowering therapy who remain on the medication therapy.</p>
<p>Patients with risk factors for coronary heart disease but no history of disease who receive lipid-lowering therapy are likely to experience a decreased risk of coronary heart disease (Sever et al., 2003; "Major outcomes," 2002; Heart Protection Study Collaborative Group, 2002; Shepherd et al., 2002; Pignone, Phillips, &amp; Mulrow, 2000; Downs et al., 1998; Shepherd et al., 1995; Frick et al., 1987; Lipid Research Clinics Program, 1984).</p>
<p>Patients with a history of coronary disease (including unstable angina and acute myocardial infarction) often benefit from treatment with a statin. Studies have consistently shown a decrease in risk of death from coronary heart disease (Cannon et al., 2004; Nissen et al., 2004; Heart Protection Study Collaborative Group, 2002; Shepherd et al., 2002; LaRosa, He, &amp; Vupputuri, 1999; Goldberg et al., 1998; The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, 1998; Scandinavian Simvastatin Survival Study Group, 1994).</p>
<p>Reducing LDL-cholesterol (LDL-C) levels is the primary approach to lowering risk of CHD in both primary and secondary prevention. Statins are the drugs of choice for lowering LDL-C, and aggressive treatment with statins should be pursued. Seven statins are available: atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, pitavastatin.</p>
<p>Poor adherence can limit the effectiveness of therapies. In asymptomatic conditions such as hyperlipidemia, this can be especially problematic. Long-term adherence to drug therapy for chronic conditions is estimated to be only about 50%. Adherence in clinical trials is often much higher, due to multiple factors including patient selection, close monitoring and educational efforts of medical staff. </p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Rationale
</h3>
<div class='FieldValue'>
<table><tr><td>Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 2. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 8;350(15):1495-504. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15007110" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 May 27;279(20):1615-22. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9613910" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237-45. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=3313041" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation. 1998 Dec 8;98(23):2513-9. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9843456" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 Jul 6;360(9326):7-22. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12114036" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999 Dec 22-29;282(24):2340-6. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10612322" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984 Jan 20;251(3):351-64. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=6361299" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002 Dec 18;288(23):2998-3007. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12479764" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004 Mar 3;291(9):1071-80. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14996776" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ. 2000 Oct 21;321(7267):983-6. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11039962" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19;344(8934):1383-9. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7968073" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5;361(9364):1149-58. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12686036" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002 Nov 23;360(9346):1623-30. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12457784" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7566020" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998 Nov 5;339(19):1349-57. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9841303" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Woolley T, Canoniero M, Conroy W, Fareed M, Groen S, Helmrick K, Kofron P, Kottke T, Leslie S, Myers C, Needham R, O'Connor P, Peters J, Reddan J, Sorge L, Zerr B. Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2013 Nov. 49 p.  [88 references]</td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Primary Health Components
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Lipid management; atherosclerotic cardiovascular disease (ASCVD); coronary heart disease (CHD); diabetes; lipid-lowering medication; statin</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Patients with (a) established atherosclerotic cardiovascular disease (ASCVD), or (b) 10-year coronary heart disease (CHD) risk greater than or equal to 10%, or (c) diabetes and most recent low-density lipoprotein (LDL) greater than 100 mg/dL and are prescribed lipid-lowering medication (see the related "Denominator Inclusions/Exclusions" field) </p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Patients with low-density lipoprotein (LDL) greater than 100 who are prescribed a maximal recommended dose of a potent statin (see the related "Numerator Inclusions/Exclusions" field) </p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Measure
</h2>
<div class='field field_picklist-choice'>
<h3>
Type of Evidence Supporting the Criterion of Quality for the Measure
</h3>
<div class='FieldValue'>
A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence
</div>

</div>
<div class='field field_text'>
<h3>
Additional Information Supporting Need for the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Extent of Measure Testing
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>State of Use of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
State of Use
</h3>
<div class='FieldValue'>
Current routine use
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Current Use
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Application of the Measure in its Current Use
</h2>
<div class='field field_picklist-choice'>
<h3>
Measurement Setting
</h3>
<div class='FieldValue'>
Ambulatory/Office-based Care
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Professionals Involved in Delivery of Health Services
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Least Aggregated Level of Services Delivery Addressed
</h3>
<div class='FieldValue'>
Clinical Practice or Public Health Sites
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Statement of Acceptable Minimum Sample Size
</h3>
<div class='FieldValue'>
Unspecified
</div>

</div>
<div class='field field_text'>
<h3>
Target Population Age
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Target Population Gender
</h3>
<div class='FieldValue'>
Either male or female
</div>

</div>

</div>
<div class='section'>
<h2>National Strategy for Quality Improvement in Health Care
</h2>
<div class='field field_text'>
<h3>
National Quality Strategy Aim
</h3>
<div class='FieldValue'>
<ul><li>Better Care</li></ul>
</div>

</div>
<div class='field field_text'>
<h3>
National Quality Strategy Priority
</h3>
<div class='FieldValue'>
<ul><li>Prevention and Treatment of Leading Causes of Mortality</li></ul>
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) National Health Care Quality Report Categories
</h2>
<div class='field field_picklist-choice'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
Living with Illness
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>

</div>

</div>
<div class='section'>
<h2>Data Collection for the Measure
</h2>
<div class='field field_text'>
<h3>
Case Finding Period
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The time frame pertaining to data collection is annually.</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Denominator Sampling Frame
</h3>
<div class='FieldValue'>
Patients associated with provider
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Denominator (Index) Event or Characteristic
</h3>
<div class='FieldValue'>
Clinical Condition
</div>
<div class='FieldValue'>
Encounter
</div>
<div class='FieldValue'>
Therapeutic Intervention
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Denominator Time Window
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br />
Patients with (a) established atherosclerotic cardiovascular disease (ASCVD), or (b) 10-year coronary heart disease (CHD) risk greater than or equal to 10%, or (c) diabetes and most recent low-density lipoprotein (LDL) greater than 100 mg/dL and are prescribed lipid-lowering medication </p>
<p class="Note"><strong>Data Collection</strong>: Query electronic medical record (EMR) for patients seen in the clinic in the last 12 months and who fit denominator criteria.</p>
<p><strong>Exclusions</strong><br />
Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-choice-4'>
<h3>
Exclusions/Exceptions
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br />
Patients with low-density lipoprotein (LDL) greater than 100 who are prescribed a maximal recommended dose of a potent statin*</p>
<p class="Note">*Such as simvastatin, pitavastatin, rosuvastatin, or atorvastatin.</p>
<p><strong>Exclusions</strong><br />
Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Numerator Search Strategy
</h3>
<div class='FieldValue'>
Fixed time period or point in time
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Data Source
</h3>
<div class='FieldValue'>
Electronic health/medical record
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Type of Health State
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_text'>
<h3>
Instruments Used and/or Associated with the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Computation of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
Measure Specifies Disaggregation
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Scoring
</h3>
<div class='FieldValue'>
Rate/Proportion
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Interpretation of Score
</h3>
<div class='FieldValue'>
Desired value is a higher score
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Allowance for Patient or Population Factors
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Standard of Comparison
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information
</h2>
<div class='field field_text'>
<h3>
Original Title
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Percentage of patients with: (a) established ASCVD, or (b) a 10-year CHD risk &ge; to 10%, or (c) diabetes, (d) on lipid-lowering medication, and (e) most recent LDL &gt; 100 mg/dL, who are prescribed a maximal recommended dose of a potent statin (such as simvastatin, pitavastatin, rosuvastatin or atorvastatin). </p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Collection Name
</h3>
<div class='FieldValue'>
Lipid Management in Adults
</div>

</div>
<div class='field field_orglist'>
<h3>
Submitter
</h3>
<div class='FieldValue'>
Institute for Clinical Systems Improvement - Nonprofit Organization
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Developer
</h3>
<div class='FieldValue'>
Institute for Clinical Systems Improvement - Nonprofit Organization
</div>

</div>
<div class='field field_text'>
<h3>
Funding Source(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The Institute for Clinical Systems Improvement's (ICSI's) work is funded by the annual dues of the member medical groups and five sponsoring health plans in Minnesota and Wisconsin.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of the Group that Developed the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p><em>Work Group Members</em>: Tony Woolley, MD (<em>Work Group Leader</em>) (Park Nicollet Health Services) (Internal Medicine); Sarah Leslie, PharmD (Allina Medical Clinic) (Pharmacy); Beth Zerr, PharmD (Allina Medical Clinic) (Pharmacy); Sarah Groen, PharmD (HealthPartners Medical Group and Regions Hospital) (Pharmacy); Patrick O'Connor, MD (HealthPartners Medical Group and Regions Hospital) (Family Medicine); Thomas Kottke, MD (HealthPartners Medical Group and Regions Hospital) (Cardiology); Robert Needham, MD (Lakeview Clinic) (Internal Medicine); Mohammad Fareed, MD (Mayo Clinic) (Family Medicine); Marianna Canoniero, MD (Park Nicollet Health Services) (Cardiology); William Conroy, MD (Park Nicollet Health Services) (Internal Medicine); Phillip Kofron, MD, MPH (Park Nicollet Health Services) (Internal Medicine); Jodi Reddan, MS, RD, LD (Park Nicollet Health Services) (Health Education); Lindsay Sorge, PharmD, MPH (Park Nicollet Health Services) (Pharmacy); Kurt Helmrick, MPAS, PA-C (River Falls Medical Clinic) (Family Medicine); Cassie Myers (Institute for Clinical Systems Improvement [ICSI]) (Clinical Systems Improvement Facilitator); Judy Peters, DNP, RN (ICSI) (Project Manager)</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Other Potential Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The Institute for Clinical Systems Improvement (ICSI) has long had a policy of transparency in declaring potential conflicting and competing interests of all individuals who participate in the development, revision and approval of ICSI guidelines and protocols. </p>
<p>In 2010, the ICSI Conflict of Interest Review Committee was established by the Board of Directors to review all disclosures and make recommendations to the board when steps should be taken to mitigate potential conflicts of interest, including recommendations regarding removal of work group members. This committee has adopted the Institute of Medicine Conflict of Interest standards as outlined in the report Clinical Practice Guidelines We Can Trust (2011). </p>
<p>Where there are work group members with identified potential conflicts, these are disclosed and discussed at the initial work group meeting. These members are expected to recuse themselves from related discussions or authorship of related recommendations, as directed by the Conflict of Interest committee or requested by the work group.</p>
<p>The complete ICSI policy regarding Conflicts of Interest is available at the <a href="https://www.icsi.org/_asset/fwsfmi/coi_policyletter.pdf" title="ICSI Web site">ICSI Web site</a>.</p>
<p><strong>Disclosure of Potential Conflicts of Interest</strong></p>
<p><strong>Marianna J. Canoniero, MD (Work Group Member) </strong><br />
Cardiologist, Cardiology, Park Nicollet Health Services <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>William E. Conroy, MD (Work Group Member) </strong><br />
Physician, Internal Medicine, Park Nicollet Health Services <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: Minor shareholder ASTX and APS stock </p>
<p><strong>Mohammed T. Fareed, MD (Work Group Member) </strong><br />
Senior Associate Consultant/Instructor, Mayo College of Medicine; Physician, Family Medicine, Mayo Clinic <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: Colorectal Cancer Screening Guideline Work Group <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Sarah Groen, PharmD (Work Group Member) </strong><br />
Clinical Pharmacist, Pharmacy, HealthPartners Medical Group and Regions Hospital <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Kurt Helmrick, MPAS (Work Group Member) </strong><br />
Physician Assistant, General Practice, River Falls Medical Clinic <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Phillip M. Kofron, MD, MPH (Work Group Member) </strong><br />
Medical Director, Heart Disease Prevention and Lipid Clinic, General Preventive Medicine, Park Nicollet Heart and Vascular Center<br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: CAD <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None</p>
<p><strong>Thomas E. Kottke, MD, MSPH (Work Group Member) </strong><br />
Medical Director Population Health, Cardiology, HealthPartners Medical Group and Regions Hospital <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Sarah L. Leslie, PharmD (Work Group Member) </strong><br />
Pharmacy Coordinator, Pharmacy, Allina Health &ndash; New Ulm Medical Center <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Robert Needham, MD (Work Group Member) </strong><br />
Physician, Internal Medicine, Lakeview Clinic <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Patrick J. O'Connor, MD, MPH (Work Group Member) </strong><br />
Senior Research Investigator, Family Medicine and Geriatrics, HealthPartners Medical Group and Regions Hospital <br />
National, Regional, Local Committee Affiliations: Midwest Research Network <br />
Guideline Related Activities: ICSI Diagnosis and Management of Type 2 Diabetes Mellitus in Adults, Hypertension Diagnosis and Treatment, Prevention and Diagnosis of Obesity, and Healthy Lifestyles <br />
Research Grants: NIH grant pending for Diabetes and Hypertension <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Jodi A. Reddan, MS, RD, LD (Work Group Member) </strong><br />
Clinical Dietician, Nutrition, Park Nicollet Health Services <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Lindsay Sorge, PharmD, MPH (Work Group Member) </strong><br />
Medication Management, Pharmacist, Park Nicollet Health Services <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Tony Woolley, MD (Work Group Leader) </strong><br />
Consultant, Clinical Associate Professor of Medicine, Internal Medicine/Hypertension, Park Nicollet Health Services <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None </p>
<p><strong>Beth Zerr, PharmD, BCACP (Work Group Member) </strong><br />
Ambulatory Pharmacist Practitioner, Pharmacy, Allina Medical Clinic <br />
National, Regional, Local Committee Affiliations: None <br />
Guideline Related Activities: None <br />
Research Grants: None <br />
Financial/Non-Financial Conflicts of Interest: None</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_date'>
<h3>
Date of Most Current Version in NQMC
</h3>
<div class='FieldValue'>
2013 Nov
</div>

</div>
<div class='field field_text'>
<h3>
Measure Maintenance
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Scientific documents are revised every 12 to 24 months as indicated by changes in clinical practice and literature.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Date of Next Anticipated Revision
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The next scheduled revision will occur within 24 months.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the measure.</p>
<p>The measure developer reaffirmed the currency of this measure in January 2016.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Source available from the <a href="https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_cardiovascular_guidelines/lipid/" title="ICSI Web site">Institute for Clinical Systems Improvement (ICSI) Web site</a>.</p>
<p>For more information, contact ICSI at 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; Phone: 952-814-7060; Fax: 952-858-9675; Web site: <a href="http://www.icsi.org" title="ICSI Web site">www.icsi.org</a>; E-mail: <a href="mailto:icsi.info@icsi.org">icsi.info@icsi.org</a>.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NQMC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary was completed by ECRI Institute on July 2, 2014.</p>
<p>The information was reaffirmed by the measure developer on January 13, 2016.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions. </p>
<p>The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties. </p>
<p>If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc. </p>
<p>All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures. </p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Production
</h2>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Woolley T, Canoniero M, Conroy W, Fareed M, Groen S, Helmrick K, Kofron P, Kottke T, Leslie S, Myers C, Needham R, O'Connor P, Peters J, Reddan J, Sorge L, Zerr B. Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2013 Nov. 49 p.  [88 references]</td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NQMC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.</p> 
<p>All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.</p> 
<p>Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NQMC Inclusion Criteria</a>.</p> 
<p>NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding measure content are directed to contact the measure developer.</p>
</div>

</div>

</div>
</body></html>